<span item_type="fundamental" item_id="6845dfbbe174fd97244b550a47033fe1" counter_id="ST/US/FTIIW" env="prod"></span><span item_type="announcement" item_id="552357503584441601" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD -0.19.</p><p></p><h3>Segment Revenue</h3><ul><li>The company has not generated any operating revenues as of June 30, 2025, and will not generate any until after the completion of its initial Business Combination.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225025250/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Net loss for the three months ended June 30, 2025, was - $80,647, compared to a net loss of - $44,457 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225025250/form10-q.htm"></span></li><li>Net loss for the six months ended June 30, 2025, was - $370,320, compared to a net income of $85,119 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225025250/form10-q.htm"></span></li><li>Total expenses for the three months ended June 30, 2025, were $138,735, compared to $284,894 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225025250/form10-q.htm"></span></li><li>Total expenses for the six months ended June 30, 2025, were $592,572, compared to $595,828 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225025250/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities for the six months ended June 30, 2025, was - $1,187,204.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225025250/form10-q.htm"></span></li><li>Net cash provided by investing activities for the six months ended June 30, 2025, was $17,585,764, primarily due to cash withdrawn from the Trust Account.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225025250/form10-q.htm"></span></li><li>Net cash used in financing activities for the six months ended June 30, 2025, was - $16,294,605, primarily due to cash paid for redemptions.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225025250/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Interest income earned on investments held in the Trust Account for the six months ended June 30, 2025, was $272,304.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225025250/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><h4>Core Business Focus</h4><ul><li>The company is focused on completing its initial Business Combination, with a proposed merger with Longevity Biomedical, Inc. being a key strategic initiative.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225025250/form10-q.htm"></span></li><li>The company has extended its deadline to complete a Business Combination to August 18, 2026, with monthly extensions contingent on deposits into the Trust Account.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225025250/form10-q.htm"></span></li></ul><h4>Non-Core Business</h4><ul><li>The company has entered into a Subscription Agreement for a Private Placement contingent upon the Business Combination with Longevity, which includes issuing additional shares under certain conditions.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225025250/form10-q.htm"></span></li></ul><h4>Priority</h4><ul><li>The company is prioritizing the completion of the Business Combination with Longevity Biomedical, Inc., which is expected to result in a name change and listing on the Nasdaq Stock Market under the ticker symbol ‘LBIO’.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225025250/form10-q.htm"></span></li></ul>

FUTURETECH II ACQUISITION CORP C/WTS 18/08/2028 (TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -0.19